Grifols announced that it has a robust inventory of HyperRAB S/D (rabies immune globulin [human]) to overcome the supply shortage caused by an increase in rabies exposures during 2012.

Currently, HyperRAB S/D is the only immune globulin available in sufficient quantities to meet the market demand for rabies post-exposure prophylaxis. This is followed by a series of rabies vaccines to generate permanent immunity.

HyperRAB S/D provides immediate immune protection to patients who are exposed to rabies but have not yet been vaccinated against the virus.

For more information call 800-243-4153 or visit